Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon-alpha induced Raynaud's syndrome.

W H Kruit1, A M Eggermont, G Stoter

  • 1Department of Medical Oncology, Rotterdam Cancer Institute/University Hospital Rotterdam, The Netherlands. kruit@onch.azr.nl

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|January 6, 2001
PubMed
Summary

Interferon-alpha (IFN-alpha) therapy can cause Raynaud's syndrome in patients with melanoma. This case study reviews symptoms, mechanisms, and treatments for this adverse effect.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Nature communications·2017
Same author

Pregnancy and melanoma: a European-wide survey to assess current management and a critical literature overview.

Journal of the European Academy of Dermatology and Venereology : JEADV·2016
Same author

Management of psychiatric adverse events with immunotherapy with interferon-alfa.

Acta neuropsychiatrica·2016
Same author

The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2015
Same author

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2015

Area of Science:

  • Immunology
  • Oncology
  • Dermatology

Background:

  • Interferon-alpha (IFN-alpha) is a cytokine used to treat viral hepatitis and malignancies.
  • Adjuvant therapy with IFN-alpha is employed for high-risk melanoma.
  • Adverse effects of IFN-alpha therapy require careful monitoring and management.

Observation:

  • Two patients developed Raynaud's syndrome during IFN-alpha treatment for melanoma.
  • Raynaud's syndrome is characterized by episodic vasospasm in extremities.

Findings:

  • IFN-alpha may trigger Raynaud's syndrome through immune-mediated or direct vascular effects.
  • Literature review details symptomatology, pathophysiology, and treatment options.

Implications:

Related Experiment Videos

  • Clinicians should monitor for Raynaud's syndrome in patients receiving IFN-alpha.
  • Early recognition and management can mitigate complications of IFN-alpha-induced Raynaud's syndrome.